GSK plc (LON:GSK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of GSK plc (LON:GSK) have been given a consensus rating of “Moderate Buy” by the seven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 1,805.83 ($22.27).

A number of brokerages have recently issued reports on GSK. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank lowered their price objective on shares of GSK from GBX 1,820 ($22.44) to GBX 1,600 ($19.73) and set a “buy” rating on the stock in a research report on Friday, November 29th.

GSK Stock Performance

GSK stock opened at GBX 1,354 ($16.70) on Tuesday. The firm has a 50-day moving average price of GBX 1,343.53. The stock has a market cap of £55.24 billion, a P/E ratio of 1,198.23, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. GSK has a fifty-two week low of GBX 1,282.50 ($15.81) and a fifty-two week high of GBX 1,823.50 ($22.48).

GSK Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Thursday, January 9th. Investors of record on Thursday, November 14th were given a GBX 15 ($0.18) dividend. The ex-dividend date was Thursday, November 14th. This represents a dividend yield of 1.03%. GSK’s dividend payout ratio is presently 5,309.73%.

Insider Transactions at GSK

In related news, insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction on Friday, December 20th. The shares were bought at an average price of GBX 1,315 ($16.21) per share, for a total transaction of £19,725 ($24,321.82). Insiders acquired a total of 8,658 shares of company stock valued at $11,950,792 in the last ninety days. Corporate insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.